The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
NCT04017897
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
52
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)
Sponsor
Yonsei University